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Acceleration of fetal maturation by intra-amniotic
administration of thyroxine
ADAMSONS,Κ. , J.ROMAGUERA, R.C.WALLACH
Spontaneously occurring Hyperthyroidism of the fetus se-
condary to transplacentally acquired LATS, has been
known to accelerate markedly fetal maturation, inclu-
ding that of the skeletal system.
The purpose of this study was to examine the effec-
tiveness of induced fetal hyperthyroidism upon the rate
of fetal maturation among patients who were likely to
go into pre-term labor, or in whom pre-term delivery
hat been planned either for maternal or fetal indica-
tions .
The present report summarizes our experience of the
initial 15 patients (Fig.1) . Indications for thyroxine
therapy. Maternal indications
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29.6-35.3 Fetal indications included,
hemolytic anemia due to Rh-
antibodies, MECKELS syndrome
7-9 (renal and CNS malformation) of
one of the twins, triplet ge-
~ ~ s t a t i o n , a n d pre-term rupture
of membranes. Evaluation of mother and fetus prior to
the administration of thyroxine. The assessment con-
sisted of documentation of fetal age by history and
sonographic measurements of the fetus, maternal T3 / T4
and TSH, frequency of fetal heart rate and fetal move-
ments (as detected by mother), and composition of amnio-
tic fluid (L/S, Creatinine and Bilirubin).
Thyroxine was injected into the amniotic space in
doses ranging from 2OO to 5OO mg and was repeated ei-
ther weekly or in a 3 day interval.
The indicators used to assess the impact of thyro-
xine therapy upon mother and fetus were identical with
those used for initial assessment, except for signs and
symptoms suggestive of maternal hyperthyroidism (eq.
palpitations, anxiety and insomnia).
Only 3 of the 15 mothers displayed signs of mild and
transient hyperthyroidism which was observable 48 hours
after the administration of the second dose and disap-
peared within 2 days.
There was an increase Of fetal movement (both fre-
quency and intensity) all instances, which increase was
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noted first after 48 hours of the initial dose of thy-
roxine.
Heart rate of the fetus increased only ifioderately
ranging from 5 to 2O beats per minute.
The pre-treatment L/S had a mean value of 1.16 and
the mean of the gestational ge was 3O. 6 weeks (Fig.2
and 3 ) . Although the mean duration of therapy to reach
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an L/S 2 was 11.4 days, the median was only 7 days.
In 2 patients a change of L/S from 1.43 ana 1.75 to
2.35 and 2. 6O respectively occurred in less than 4 days.
P.G.Values were obtained on only one patient, in
whom it changed from undetectable to 3.3 over a period
of one week.
It is evident that L/S of the treated population
differ markedly from those derived from a large control
group (dotted line).
Although in one case L/S of 2 . 4 was observed at
29 .6 weeks of gestation following 4 weeks of thyroxine
therapy, in all others the principal change occurred be-
tween the 31 and 33 weeks. The lesser responsiveness of
the younger fetuses might be explained on the basis of
their limited capacity to transform the adminstered T^
into Τ 3.
Effect on growth and general maturation of the fetus
was assessed by comparing birth weight and DUBOWITZ
scores against respective standards at matched gesta-
tional age. Reference standard for expected birth
weight was 5O percentile of the LUBCHENKO nomogram.
The mean birth weight was 258 grams above that pre-
dicted from the nomogram, and the mean of the DUBOWITZ
score was 2 . 2 6 weeks ahead of the chronologic age of the
fetus.
Bone age was determined only on one infant; it was 3
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weeks above the chronologic age. Neonatal complications
consisted of mild RDS in 1 of 16 newborns, transient
tachypnea in 3, and in-utero acquired pneumonia in 2.
Only two of the newborns required assisted ventilation.
All newborns were enrolled in a special surveillance
program under the direction of a pediatric endocrinolo-
gist.
Follow-up to date has failed to disclose any unusual
clinical problems. Only one of the 16 newborns received
thyroxine postnatally for reasons unrelated to clini-
cally detectable Hypothyroidism. None had suppressed
TSH levels, or abnormal T3 or T^ concentrations. The
triplets exhibited an above average growth pattern for
the first two months, and received blood transfusion
for anemia.
Our inital experience supports the view that a rela-
tively mild degree of fetal hyperthyroidism brought
about by intraamniotic administration of thyroxine,
accelerates fetal maturation, while at the same time
increasing fetal growth. Thyroxine appears to be supe-
rior to glucocorticoids to prevent sequelae of immatu-
rity.
It is probable that T3 is even more efficatious to
achieve this objective than 14, due to the limited ca-
pacity of the younger fetus to transform T4 into T3.
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